Henriëtte Lanz,
Director, Model Development,
MIMETAS BV
Henriette Lanz is Director of the Model Development R&D team at Mimetas. She has received her PhD in Molecular Biology from Leiden University in 2012, and a cum laude masters in Life Science Technologies. She worked on cancer-selective target discovery at Leiden University and secondary metabolite production at Explant Technologies. In her current role at Mimetas she supervises a team of senior and junior scientists and technicians, alongside PhD and MSc students. The specific focus of her research activities at Mimetas are the development of organotypic models for drug screening and toxicity evaluation within the fields of kidney, vasculature, and cancer.
High Throughput Phenotypic Screening with Organ on a Chip
Monday, 24 October 2022 at 15:00
Add to Calendar ▼2022-10-24 15:00:002022-10-24 16:00:00Europe/LondonHigh Throughput Phenotypic Screening with Organ on a ChipBioengineering for Building Microphysiological Systems 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Organ-on-a-Chip is a powerful technology driving physiological relevance by utilizing microfluidic techniques. The technology is expected to impact drug development and ultimately replace or reduce animal testing. Since most platform technologies are either based on single chips or small numbers of chips in dedicated surroundings, application for Organ-on-a-chip is largely envisioned in pre-clinical testing, such as preclinical safety, pharmacology, or pharmacokinetics. Thus far it was thought that with the advanced complexity of models prevents use in drug discovery studies. The OrganoPlate is an exception to this rule, as it comprises 40 to 96 chips. The microtiter plate footprint renders it fully compatible with automated imaging and robotic handling. In fact, Kane et al. reported automation of the platform for long term maintenance of dopaminergic neurons in a Parkinson’s Disease study. High throughput screening applications utilizing Organ-on-a-Chip technology, however have thus far not been reported. Here we report a 1500+ compound screen on a 3D angiogenic sprouting assay. We utilized a newly developed platform, the OrganoPlate 3-lane 64, which comprises 64 chips underneath a microtiter plate. Similar to other versions of the OrganoPlate platform, it utilizes surface tension techniques to stratify extracellular matrix gels and tissue layers and employs passive leveling between reservoirs for inducing flow. Each chip comprises a gel lane and is flanked by two perfusion lanes. Human Umbilical Vein Endothelial Cell (HUVEC) microvessels were grown against a collagen gel according to previously reported protocols. The effect of a small molecule protein kinase inhibitor library of over 1500 compounds was assessed on the angiogenic sprouting behavior of the vessels. The microvessels were exposed to an optimized cocktail of angiogenic factors in conjunction with the compound utilizing automated liquid handling. Readouts including sprout length, sprout and microvessel morphological changes were used. Cultures were imaged using a high content device (Molecular Devices, ImageXpress Micro Confocal). The screen yielded a limited number of hits that either enhanced or inhibited angiogenic capacity. The OrganoPlate 3-lane 64 showed considerable benefit over its predecessor, the OrganoPlate 3-lane 40, not only due to the increased density of chips, but also its 8-well pipette pitch for functionally similar inlets and outlets. This is the first time that Organ-on-a-Chip is reported to be utilized in a large library screen, opening up the route towards early drug screening on tissue models of unrivaled physiological relevance.
Add to Calendar ▼2022-10-24 00:00:002022-10-25 00:00:00Europe/LondonBioengineering for Building Microphysiological Systems 2022Bioengineering for Building Microphysiological Systems 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-10-24 15:00:002022-10-24 16:00:00Europe/LondonHigh Throughput Phenotypic Screening with Organ on a ChipBioengineering for Building Microphysiological Systems 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
